The company said net sales for Q2 2024 fell to $702.1 million, down 6.9% from a year earlier, and organic net sales declined 5.9%. Reported-diluted EPS was $1.51, compared with $2.06 a year earlier.

1. 01

   The company said net sales for Q2 2024 fell to $702.1 million, down 6.9% from a year earlier, and organic net sales declined 5.9%. Reported-diluted EPS was $1.51, compared with $2.06 a year earlier.

2. 02

   West Pharmaceutical said Proprietary Products net sales fell 9.4% to $559.7 million in Q2, while Contract-Manufactured Products net sales rose 4.9% to $142.4 million. The company said Q2 continued to be affected by an elevated level of customer destocking.

3. 03

   The company said operating cash flow for the first half of 2024 was $283.2 million, down 7.8%, and free cash flow was $92.4 million, down 38.3%. During the same period, it repurchased 1,239,015 shares for $454.1 million.

4. 04

   The company updated its full-year 2024 net sales outlook to a range of $2.870 billion to $2.900 billion, from a prior range of $3.000 billion to $3.025 billion. It also updated its full-year adjusted-diluted EPS outlook to a range of $6.35 to $6.65, from a prior range of $7.63 to $7.88.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.